Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Juan Jaen
AddedFeb 15, 2024
UpdatedJun 28, 2026
Juan Jaen

Juan Jaen

Co-Founder, Arcus Biosciences

CrunchbaseLinkedInThe Org

Juan Jaen's Career

Arcus Biosciences
Arcus Biosciences

Hayward, CA, US

Co-Founder
Shasqi
Shasqi

San Francisco, CA, US

Board Member· Board
Hexagon Bio
Hexagon Bio

Menlo Park, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Juan Jaen's Career

Arcus Biosciences
Arcus Biosciences
Public$967M5502015Hayward, CA, US
Co-Founder

Leadership at Arcus Biosciences

Nicole LambertNicole LambertBoard Member
Terry RosenTerry RosenCEO
Kate FalbergKate FalbergBoard Member
Yasunori KanekoYasunori KanekoBoard Member
Jennifer JarrettJennifer JarrettBoard Member
Patrick MachadoPatrick MachadoBoard Member
Shasqi
Shasqi
Seed$65.4M242015San Francisco, CA, US
Board Member· Board

Leadership at Shasqi

Jose M. Mejia OnetoJose M. Mejia OnetoFounder & CEO
José M. Mejía OnetoJosé M. Mejía OnetoFounder & CEO

Similar to Shasqi

Asher BioAsher BioSouth San Francisco, CA, USCancer Treatment, Immunotherapyest. 2019Asher BioSouth San Francisco, CA, US · est. 2019

Asher Bio crafts targeted immunotherapies for cancer and diseases, focusing on precision and innovation.

Series B · $163.2M56
AlixiaAlixiaSan Francisco, CA, USest. 2022AlixiaSan Francisco, CA, US · est. 2022

Alixia: Innovating lasting cancer treatments by targeting the tumor ecosystem and disrupting key triggers.

Seed · $500k5
BloodQBloodQOrinda, CA, USCancer Treatment, DiagnosticsBloodQOrinda, CA, US

BloodQ offers personalized cancer treatment through its innovative diagnostic platform analyzing circulating DNA.

Seed · $4.5M2
Palm TherapeuticsPalm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7
Hexagon Bio
Hexagon Bio
Series B$193.6M832016Menlo Park, CA, US
Board Member· Board

Leadership at Hexagon Bio

David GoeddelDavid GoeddelBoard Member
Jakob LovenJakob LovenBoard Member
Brian NaughtonBrian NaughtonCo-Founder
Maureen HillenmeyerMaureen HillenmeyerCo-Founder

Juan Jaen's Co-Investors

Bill RieflinBill RieflinCo-invested · Shasqi Series B

Juan Jaen's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Juan Jaen

Caroline LandauCaroline LandauCo-Founder · PreDxion BioKunal GosarKunal GosarCo-Founder · ArcusChristopher GarciaChristopher GarciaBoard Member · Arcus Biosciences